Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment

Journal of Thoracic Oncology

Volumn 11, Issue 1, 2016, Pages e1-e4

  Ham, Jun Soo ^a   Kim, Seokhwi ^a   Kim, Hee Kyung ^a   Byeon, Seonggyu ^a   Sun, Jong Mu ^a   Lee, Se Hoon ^a   Ahn, Jin Seok ^a   Park, Keunchil ^a   Choi, Yoon La ^a   Han, Joungho ^a   Park, Woongyang ^b,c   Ahn, Myung Ju ^a  

^a Samsung Medical Center   (South Korea)

^b Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CARBOPLATIN; CD56 ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; OSIMERTINIB; PEMETREXED; ACRYLAMIDE DERIVATIVE; ANILINE DERIVATIVE; EGFR PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CARCINOGENESIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE COURSE; DISEASE EXACERBATION; DRUG RESPONSE; DYSPNEA; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE DELETION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG METASTASIS; LUNG SURGERY; MIDDLE AGED; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT DISEASE; SMALL CELL LUNG CANCER; THORAX RADIOGRAPHY; TREATMENT DURATION; ADENOCARCINOMA; CELL TRANSFORMATION; CLINICAL TRIAL; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

ACRYLAMIDES; ADENOCARCINOMA; ANILINE COMPOUNDS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA;

EID: 84959377108     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.09.013     Document Type: Article

References (6)

1. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
2. Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165-e172.
3. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-1061.
4. Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689-1699.
5. Piotrowska Z, Niederst MJ, Karlovich CA, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 2015;5:713-722.
6. Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560-562.